Skip to content
PeptideTech
sign in
live116 compounds · 15 vendors listed · 7 graded · audit of 4 Nov 2026 · prices checked 6 Nov 2026independent · grades can’t be bought

Home / Research library / ARA-290

Peptides

ARA-290: molecular data, studies & sources

ARA-290 is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF)
C51H84N16O21
Molecular weight (MW)
1257.3 g/mol
PubChem compound ID
91810664
Record title
Cibinetide

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 91810664 · retrieved 2026-09-21

2D molecular structure for ARA-290, PubChem CID 91810664
2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.
Chemical identifiers and source data
IUPAC name
(4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid
InChIKey
WZTIQQBMSJTRBR-WYKNNRPVSA-N
SMILES
C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCC(=O)N1
Machine-readable PubChem source

Identifiers & sequence

PubChem CID
91810664
CAS Registry Number
1208243-50-8via ChemIDplus, EPA DSSTox, FDA GSRS
FDA UNII
9W5677JKDA
ChEMBL ID
CHEMBL3545305
InChIKey
WZTIQQBMSJTRBR-WYKNNRPVSA-N
Wikidata
Q27273306

Peptide sequence · 11 residues (one-letter code; X marks a residue without a one-letter code)

XEQLERALNSS

Condensed notation with terminal groups and non-standard residues

H-Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH

Source: PubChem Biologic Line Notation. A reference sequence for the record, not an analysis of a supplied batch.

CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-07.

Calculated molecular descriptors
Monoisotopic (exact) mass1256.5997 Da
Heavy atoms88
Hydrogen-bond donors20
Hydrogen-bond acceptors19
Rotatable bonds42
Topological polar surface area623.0 Ų
Calculated logP (Crippen)-8.78
Rings1
Stereocenters11
Formal charge0

Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.

US regulatory status & drug development

Drugs@FDA lists no NDA, BLA or ANDA with cibinetide as an active ingredient (names searched: CIBINETIDE, ARA-290; checked October 7, 2026). Research-labelled ARA-290 listings are not FDA-approved drugs.

An FDA approval covers a defined medicine, formulation and labelled use. It does not extend to research-labelled material sold under the same compound name. Identity basis: INN cibinetide and the code ARA-290 were searched.

Source: Drugs@FDA via openFDA (active-ingredient search for CIBINETIDE, ARA-290) · checked . openFDA data are not intended for clinical decisions.

Drug development record (ChEMBL)

Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.

ChEMBL ID
CHEMBL3545305
Modality
Protein / peptide
Highest clinical stage
Phase 2
Record name
CIBINETIDE

Mechanism of action

  • Innate repair receptor agonist · target: Innate repair receptor (CSF2RB)
Synonyms, codes and trade names
Synonyms and development codes
ARA 290 · ARA-290 · ARA290 · Cibinetide

Identity check: Identical standard InChIKey to the PubChem record. Source: ChEMBL CHEMBL3545305 (EMBL-EBI, CC BY-SA 3.0) · retrieved 2026-10-07

Registered clinical trials

Studies registered on ClinicalTrials.gov that list ARA-290 as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

2 registered studies matched, 1 with results posted on ClinicalTrials.gov.

By highest phase
Phase 2 · 2
By registry status
Completed · 1Unknown · 1
StudyPhase · statusConditionsSponsor · size
Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With SarcoidosisNCT02039687 · start 2014-01 · primary completion 2015-01Phase 2CompletedResults posted 2017-01-18Neuropathy of SarcoidosisAraim Pharmaceuticals, Inc.64 participants
ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)NCT01933529 · start 2013-10 · primary completion 2014-06Phase 2UnknownDiabetes Type 2 · Impaired Glucose Tolerance · Impaired Fasting GlucoseClaes-Göran Östenson24 participants

Registry check 2026-10-09 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received ARA-290, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

  1. Human study · PubMed trial index Compound given to participants

    Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.

    Heij L, Niesters M, Swartjes M et al. · Molecular medicine (Cambridge, Mass.) · 2012

    PMID 23168581 · DOI: 10.2119/molmed.2012.00332

  2. Human study · PubMed trial index Compound given to participants

    ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.

    Dahan A, Dunne A, Swartjes M et al. · Molecular medicine (Cambridge, Mass.) · 2013

    PMID 24136731 · DOI: 10.2119/molmed.2013.00122

  3. Human study · PubMed trial index Compound given to participants

    ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

    Brines M, Dunne AN, van Velzen M et al. · Molecular medicine (Cambridge, Mass.) · 2015

    PMID 25387363 · DOI: 10.2119/molmed.2014.00215

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

  1. Review · secondary evidence

    ARA 290 for treatment of small fiber neuropathy in sarcoidosis.

    van Velzen M, Heij L, Niesters M et al. · Expert opinion on investigational drugs · 2014

    PMID 24555851 · DOI: 10.1517/13543784.2014.892072

  2. Research publication · design requires review

    ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception.

    Zhang W, Yu G, Zhang M et al. · Peptides · 2016

    PMID 26774587 · DOI: 10.1016/j.peptides.2016.01.003

  3. Preclinical / laboratory research

    Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.

    Al-Onaizi MA, Thériault P, Lecordier S et al. · Brain, behavior, and immunity · 2022

    PMID 34343617 · DOI: 10.1016/j.bbi.2021.07.016

  4. Preclinical / laboratory research

    A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets.

    Watanabe M, Lundgren T, Saito Y et al. · Transplantation · 2016

    PMID 26683514 · DOI: 10.1097/TP.0000000000001026

ARA-290 supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

ARA-290 for sale: compare prices, sizes and forms from every tracked supplier →

SupplierRecorded packagesExample source listing
American PeptidesUSD10mg Vial1 recorded offers10mg Vial · $82.00Checked Nov 6, 2026Supplier listing, ARA-290 10mg Vial, American Peptides, opens in a new tab
Amino ClubUSD10mg Vial1 recorded offers10mg Vial · $49.99Stale observation · Checked Oct 14, 2026Supplier listing, ARA-290 10mg Vial, Amino Club, opens in a new tab
Amino USAUSD10mg Vial · 50mg Vial2 recorded offers10mg Vial · $50.00Checked Nov 6, 2026Supplier listing, ARA-290 10mg Vial, Amino USA, opens in a new tab
Cenexa LabsUSD10mg Vial1 recorded offers10mg Vial · $74.99Checked Nov 6, 2026Supplier listing, ARA-290 10mg Vial, Cenexa Labs, opens in a new tab
LA PeptidesUSD16mg Vial1 recorded offers16mg Vial · $69.99Checked Nov 3, 2026Supplier listing, ARA-290 16mg Vial, LA Peptides, opens in a new tab

Reference sources & further reading

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

Related research profiles

Peptides

BPC-157

C62H98N16O22

1419.5 g/mol · PubChem CID 9941957

7 selected publications · 1 human intervention study · 3 registered trials

Protein / peptide · highest stage: Phase 1

Structure, studies & sources →